Success Metrics

Clinical Success Rate
87.5%

Based on 7 completed trials

Completion Rate
88%(7/8)
Active Trials
1(8%)
Results Posted
29%(2 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
2
15%
Ph phase_4
3
23%
Ph early_phase_1
1
8%
Ph phase_1
1
8%
Ph phase_2
4
31%
Ph phase_3
2
15%

Phase Distribution

2

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
1(7.7%)
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
4(30.8%)
Phase 3Large-scale testing
2(15.4%)
Phase 4Post-market surveillance
3(23.1%)
N/ANon-phased studies
2(15.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

77.8%

7 of 9 finished

Non-Completion Rate

22.2%

2 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(1)
Completed(7)
Terminated(2)
Other(3)

Detailed Status

Completed7
unknown3
Terminated1
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
87.5%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (7.7%)
Phase 11 (7.7%)
Phase 24 (30.8%)
Phase 32 (15.4%)
Phase 43 (23.1%)
N/A2 (15.4%)

Trials by Status

completed754%
terminated18%
recruiting18%
unknown323%
withdrawn18%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
DRUG
Total Trials
13